{"transactions":[{"id":4627966,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":8.58,"exercise_date":"2026-09-24","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627965,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":5.36,"exercise_date":"2026-09-24","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627964,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":25000,"derivative":{"exercise_price":8.57,"exercise_date":"2026-09-24","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":4627963,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-29T01:36:32.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a \"change in control\" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025."}],"balance_after":20000,"derivative":{"exercise_price":10.09,"exercise_date":"2026-09-24","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001731122-26-001296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655366/000173112226001296/ownership.xml","form_type":"4"}},{"id":941911,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T22:26:26.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.58,"exercise_date":"2026-01-06","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-26-000035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000035/ownership.xml","form_type":"4"}},{"id":1024264,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-04T00:42:50.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":25000,"derivative":{"exercise_price":5.36,"exercise_date":"2025-10-02","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-001355","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001355/ownership.xml","form_type":"4"}},{"id":1057646,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-22T21:30:21.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.58,"exercise_date":"2025-08-20","expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-001168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001168/ownership.xml","form_type":"4"}},{"id":1163282,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T00:00:38.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.57,"exercise_date":"2025-04-28","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-000655","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000655/ownership.xml","form_type":"4"}},{"id":1299829,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-18T02:12:55.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":8.57,"exercise_date":"2025-01-15","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-25-000095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000095/ownership.xml","form_type":"4"}},{"id":1322691,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-24T00:00:31.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares."}],"balance_after":12500,"derivative":{"exercise_price":5.36,"exercise_date":"2024-12-19","expiration_date":"2034-02-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001731122-24-002045","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224002045/ownership.xml","form_type":"4"}},{"id":1340230,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-07T02:00:08.000Z","date":"2024-11-19","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 10,000 shares."}],"balance_after":20000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-11-19","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001731122-24-001952","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224001952/ownership.xml","form_type":"4"}},{"id":1679851,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-13T01:00:34.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares."}],"balance_after":10000,"derivative":{"exercise_price":10.09,"exercise_date":"2024-01-02","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001731122-24-000069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000069/ownership.xml","form_type":"4"}},{"id":2614487,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T21:36:14.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon achieving a key enrollment milestone in a late stage clinical study."}],"balance_after":40000,"derivative":{"exercise_price":18.11,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001731122-21-001302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001302/ownership.xml","form_type":"4"}},{"id":2647293,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options subject to this grant vested quarterly over a three-year period commencing on June 30, 2017."}],"balance_after":0,"derivative":{"exercise_price":5.92,"expiration_date":"2027-05-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647292,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":106696,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.28,"exercise_date":"2016-09-22","expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":106696},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647291,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options subject to this grant vested quarterly over a three-year period commencing on December 31, 2015."}],"balance_after":0,"derivative":{"exercise_price":5.68,"expiration_date":"2025-10-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647290,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":166696,"price":26.53,"value":4422444.88,"ownership":{"direct":true},"balance_after":22963,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647289,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":35000,"price":5.92,"value":207200.0,"ownership":{"direct":true},"balance_after":189659,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647288,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":106696,"price":3.28,"value":349962.88,"ownership":{"direct":true},"balance_after":154659,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2647287,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-07-02T01:45:55.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":25000,"price":5.68,"value":142000.0,"ownership":{"direct":true},"balance_after":47963,"source":{"system":"sec-edgar","filing":"0001731122-21-001126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221001126/ownership.xml","form_type":"4"}},{"id":2925166,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-04T19:26:29.000Z","date":"2020-12-30","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2/3 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome."}],"balance_after":50000,"derivative":{"exercise_price":5.49,"expiration_date":"2030-12-30","underlying":"Common stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001731122-21-000012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112221000012/ownership.xml","form_type":"4"}},{"id":3315106,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-08T23:00:29.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome."}],"balance_after":70000,"derivative":{"exercise_price":2.96,"expiration_date":"2030-01-06","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001731122-20-000024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112220000024/ownership.xml","form_type":"4"}},{"id":3396831,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-07T23:48:43.000Z","date":"2019-10-03","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.75,"expiration_date":"2022-12-13","underlying":"Common","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001062993-19-003838","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003838/form4.xml","form_type":"4"}},{"id":3396830,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-07T23:48:43.000Z","date":"2019-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.05,"expiration_date":"2022-12-13","underlying":"Common","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-19-003838","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003838/form4.xml","form_type":"4"}},{"id":3396829,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-07T23:48:43.000Z","date":"2019-10-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."}],"balance_after":30000,"derivative":{"exercise_price":1,"expiration_date":"2022-12-13","underlying":"Common","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001062993-19-003838","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003838/form4.xml","form_type":"4"}},{"id":3397516,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2019-10-04T19:12:35.000Z","date":"2019-06-25","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2022-12-13","underlying":"COMMON","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001062993-19-003822","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003822/form5.xml","form_type":"5"}},{"id":3397515,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2019-10-04T19:12:35.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019."}],"balance_after":20000,"derivative":{"exercise_price":1.75,"expiration_date":"2022-12-13","underlying":"COMMON","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001062993-19-003822","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003822/form5.xml","form_type":"5"}},{"id":3397514,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2019-10-04T19:12:35.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019."}],"balance_after":10000,"derivative":{"exercise_price":1.05,"expiration_date":"2022-12-13","underlying":"COMMON","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-19-003822","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003822/form5.xml","form_type":"5"}},{"id":3397513,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON","published_at":"2019-10-04T19:12:35.000Z","date":"2019-08-31","kind":"grant","acquired":true,"shares":5643,"price":1.25,"value":7053.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchased under Employee Stock Purchase Plan, which transactions are exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.50, inclusive. The reporting person undertakes to provide to Destiny Media Technologies Inc., any security holder of Destiny Media Technologies Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The weighted average price reported above was converted from the Canadian weighted average price of C$1.66 to USD using an exchange rate of CAD $1.3294=USD $1.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019."}],"balance_after":15984,"source":{"system":"sec-edgar","filing":"0001062993-19-003822","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299319003822/form5.xml","form_type":"5"}},{"id":3498545,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T23:27:48.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon the achievement by the Company of 100% patient enrollment in the Company's Phase 2b/3 Alzheimer's disease and Phase 2 Parkinson's disease dementia clinical trials."}],"balance_after":35000,"derivative":{"exercise_price":2.93,"expiration_date":"2029-06-04","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-19-010249","document":"s113104_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000121390019010249/s113104_form4.xml","form_type":"4"}},{"id":3798140,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-03T21:29:21.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials."}],"balance_after":27300,"derivative":{"exercise_price":2.58,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":27300},"source":{"system":"sec-edgar","filing":"0001615774-18-010439","document":"s113104_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000161577418010439/s113104_form4.xml","form_type":"4"}},{"id":3927596,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T21:23:09.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones."}],"balance_after":30000,"derivative":{"exercise_price":2.3,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001615774-18-004023","document":"s110300_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000161577418004023/s110300_form4.xml","form_type":"4"}},{"id":4079949,"issuer":{"id":8237,"kind":"organization","name":"DESTINY MEDIA TECHNOLOGIES INC","symbol":"DSNY"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common","published_at":"2018-02-02T21:39:43.000Z","date":"2018-01-31","kind":"other","acquired":true,"shares":46207,"price":0.26,"value":12013.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Purchased under Employee Stock Purchase Plan, which transaction is exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"$0.3212 Canadian Dollars, based on exchange rate of 0.8135."}],"balance_after":51707,"source":{"system":"sec-edgar","filing":"0001062993-18-000422","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099369/000106299318000422/form4.xml","form_type":"4"}},{"id":4130088,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-15T21:11:52.000Z","date":"2017-12-13","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest quarterly over a three-year period commencing on March 31, 2018."}],"balance_after":30000,"derivative":{"exercise_price":3.3,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001615774-17-007357","document":"s108450_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000161577417007357/s108450_form4.xml","form_type":"4"}},{"id":4320434,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-15T21:14:29.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest quarterly over a three-year period commencing on June 30, 2017."}],"balance_after":35000,"derivative":{"exercise_price":5.92,"expiration_date":"2027-05-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001615774-17-002450","document":"s106223_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000161577417002450/s106223_form4.xml","form_type":"4"}},{"id":4594967,"issuer":{"id":6086,"kind":"organization","name":"ANAVEX LIFE SCIENCES CORP.","symbol":"AVXL"},"owners":[{"id":69640,"kind":"person","name":"Boenisch Sandra","position":1,"cik":"0001655366","reported_name":"Boenisch Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-26T21:14:53.000Z","date":"2016-09-22","kind":"grant","acquired":true,"shares":106696,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":106696,"derivative":{"exercise_price":3.28,"exercise_date":"2016-09-22","expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":106696},"source":{"system":"sec-edgar","filing":"0001615774-16-007380","document":"s104215_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314052/000161577416007380/s104215_form4.xml","form_type":"4"}}]}